These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 12187178)
1. Health services utilization with reference drug pricing of histamine(2) receptor antagonists in British Columbia elderly. Hazlet TK; Blough DK Med Care; 2002 Aug; 40(8):640-9. PubMed ID: 12187178 [TBL] [Abstract][Full Text] [Related]
2. Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia. Marshall JK; Grootendorst PV; O'Brien BJ; Dolovich LR; Holbrook AM; Levy AR CMAJ; 2002 Jun; 166(13):1655-62. PubMed ID: 12126319 [TBL] [Abstract][Full Text] [Related]
3. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526 [TBL] [Abstract][Full Text] [Related]
4. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. Schneeweiss S; Soumerai SB; Glynn RJ; Maclure M; Dormuth C; Walker AM CMAJ; 2002 Mar; 166(6):737-45. PubMed ID: 11944760 [TBL] [Abstract][Full Text] [Related]
5. Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents. Schneeweiss S; Dormuth C; Grootendorst P; Soumerai SB; Maclure M Med Care; 2004 Jul; 42(7):653-60. PubMed ID: 15213490 [TBL] [Abstract][Full Text] [Related]
6. Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. Grootendorst PV; Dolovich LR; O'Brien BJ; Holbrook AM; Levy AR CMAJ; 2001 Oct; 165(8):1011-9. PubMed ID: 11699696 [TBL] [Abstract][Full Text] [Related]
7. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. Schneeweiss S; Walker AM; Glynn RJ; Maclure M; Dormuth C; Soumerai SB N Engl J Med; 2002 Mar; 346(11):822-9. PubMed ID: 11893794 [TBL] [Abstract][Full Text] [Related]
8. Prescription duration after drug copay changes in older people: methodological aspects. Schneeweiss S; Maclure M; Soumerai SB J Am Geriatr Soc; 2002 Mar; 50(3):521-5. PubMed ID: 11943050 [TBL] [Abstract][Full Text] [Related]
9. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Duetz MS; Schneeweiss S; Maclure M; Abel T; Glynn RJ; Soumerai SB Clin Ther; 2003 Jan; 25(1):273-84. PubMed ID: 12637126 [TBL] [Abstract][Full Text] [Related]
10. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of H2-receptor antagonists. Andrade SE; Gurwitz JH; Fish LS Med Care; 1999 Apr; 37(4):424-30. PubMed ID: 10213023 [TBL] [Abstract][Full Text] [Related]
11. The Impact of reference pricing on prescribing patterns, costs, and health services utilization of proton pump inhibitors: A quasi-experimental study in British Columbia, Canada. Au SW; Law MR; Cheng L; McGrail K; Harrison M Health Policy; 2024 Jun; 144():105061. PubMed ID: 38676977 [TBL] [Abstract][Full Text] [Related]
12. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population. Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310 [TBL] [Abstract][Full Text] [Related]
13. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Schneeweiss S; Maclure M; Dormuth CR; Glynn RJ; Canning C; Avorn J Clin Pharmacol Ther; 2006 Apr; 79(4):379-88. PubMed ID: 16580906 [TBL] [Abstract][Full Text] [Related]
14. Policy analysis of the conversion of histamine2 antagonists to over-the-counter use. Kalish SC; Bohn RL; Avorn J Med Care; 1997 Jan; 35(1):32-48. PubMed ID: 8998201 [TBL] [Abstract][Full Text] [Related]
15. Evaluating reference-based pricing: initial findings and prospects. Narine L; Senathirajah M; Smith T CMAJ; 1999 Aug; 161(3):286-8. PubMed ID: 10463052 [TBL] [Abstract][Full Text] [Related]
16. Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program. Anderson GM; Kerluke KJ; Pulcins IR; Hertzman C; Barer ML Inquiry; 1993; 30(2):199-207. PubMed ID: 8314608 [TBL] [Abstract][Full Text] [Related]
17. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Grootendorst PV; Marshall JK; Holbrook AM; Dolovich LR; O'Brien BJ; Levy AR Health Serv Res; 2005 Oct; 40(5 Pt 1):1297-317. PubMed ID: 16174135 [TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. Tamblyn R; Laprise R; Hanley JA; Abrahamowicz M; Scott S; Mayo N; Hurley J; Grad R; Latimer E; Perreault R; McLeod P; Huang A; Larochelle P; Mallet L JAMA; 2001 Jan 24-31; 285(4):421-9. PubMed ID: 11242426 [TBL] [Abstract][Full Text] [Related]
19. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. Schneeweiss S; Maclure M; Carleton B; Glynn RJ; Avorn J BMJ; 2004 Mar; 328(7439):560. PubMed ID: 14982865 [TBL] [Abstract][Full Text] [Related]
20. A re-examination of the impact of reference pricing on anti-hypertensive drug plan expenditures in British Columbia. Grootendorst P; Stewart D Health Econ; 2006 Jul; 15(7):735-42. PubMed ID: 16498702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]